Recursion Pharmaceuticals misses Q1 operating revenue estimates, net loss narrows

Recursion Pharmaceuticals

06/05/2026 11:43

Overview

US drug discovery firm's Q1 operating revenue missed analyst expectations

Q1 net loss narrowed, helped by lower R&D and admin costs

Company reiterates 2026 operational cash burn guidance, expects cash runway into early 2028

Outlook

Recursion reiterates 2026 guidance of less than $390 mln operational cash burn

Company expects cash runway to extend into early 2028 without additional financing

Regulatory update for REC-4881 expected in 2H26; additional Phase 1 data for REC-1245 in 2H26

Result Drivers

LOWER ROCHE REVENUE - Q1 revenue declined mainly due to less revenue recognized from Roche after completion of certain project phases in the prior period

COST REDUCTIONS - Lower R&D and admin expenses driven by improved operating efficiency, reduced platform costs, and fewer one-time transaction costs

Company press release: ID:nGNX5ZMbJM

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Operating Revenue
Miss
$6.30 mln
$15.78 mln (8 Analysts)
Q1 Net Income
Beat
-$117.50 mln
-$132.18 mln (5 Analysts)
Q1 Pretax Profit
Beat
-$122.11 mln
-$132.67 mln (3 Analysts)
Q1 Operating Income
-$128.51 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $5.00, about 48.4% above its May 5 closing price of $3.37

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)